AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05422417 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham control
Description: Half of the patients in the sham group received 2-week the same prolonged iTBS parameter stimulation (sham- prolonged iTBS), and the other half received the same 20 Hz rTMS parameter stimulation using a sham coil (sham-20 Hz rTMS), which also improved the blinding process
Study NCT06495671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetically enhanced diffusion
Description: Iron nanoparticle (intra-arterial) + External magnet workstation
Study NCT04979559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile health apps
Description: Mobile health application intervention including screening and early intervention such as diet and physical activity suggestion
Study NCT04979559 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Regular practice for screening and early intervention for prediabetes patient in primary health cares setting
Study NCT05741580 — intervention group
Intervention type: PROCEDURE
Intervention: Evolution of symptoms
Description: percentage of patients with improvement in their symptoms
Study NCT00998179 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acu-TENS
Description: Application of Acu-TENS (with electrical output from the machine)
Study NCT00998179 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-TENS
Description: Application of Acu-TENS (without electrical output from the machine)
Study NCT05411471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain
Description: The COVID-19 vaccine (Vero cell), Inactivated, Omicron Strain was developed by Sinovac Life Science Ltd.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The antigen content is 1200 SOU/0.5 mL (6 µg/0.5 mL).
Study NCT04867837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octaplex
Description: Four-factor prothrombin complex concentrate (4F-PCC)
Study NCT05829655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug A (Blinded Drug)
Description: Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Study NCT05829655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug A (Blinded Drug)
Description: Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Study NCT05829655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug B (Blinded Drug)
Description: Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Study NCT05829655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug B (Blinded Drug)
Description: Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Study NCT05829655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug C (Blinded Drug)
Description: Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Study NCT05829655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug C (Blinded Drug)
Description: Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Study NCT05829655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug D (Blinded Drug)
Description: Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Study NCT05829655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug D (Blinded Drug)
Description: Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Study NCT04851444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-F019
Description: Single dose is administered IV.
Study NCT05829655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant (20mg/day)
Description: Double blind administration of suvorexant once per day during residential stay until discharge.
Study NCT04466917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 215
Description: ABP 215 will be administered at a dose of 15 mg/kg IV
Study NCT04466917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 15 mg/kg IV
Study NCT04466917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered 175 mg/m2 IV
Study NCT04466917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered 175 mg/m2 IV
Study NCT04466917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered at an area under the concentration-time curve (AUC) of 5 IV
Study NCT04466917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered at an area under the concentration-time curve (AUC) of 5 IV
Study NCT06577792 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lobectomy-First
Description: During the surgical treatment for patients with NSCLC, thoracic surgeons should perform lobectomy first, and then perform lymphadenectomy next.
Study NCT06577792 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lymphadenectomy-First
Description: During the surgical treatment for patients with NSCLC, thoracic surgeons should perform lymphadenectomy first, and then perform lobectomy next.
Study NCT05829655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blind administration of placebo once per day during residential stay until discharge.
Study NCT06572306 — intervention group
Intervention type: DEVICE
Intervention: FreeStyle Libre 2 Continuous Glucose Monitor
Description: Subjects included in the intervention group (continuous glucose monitoring) will be recruited from the USF Health Department of Family Medicine. Each subject will be enrolled for 12 weeks.
Study NCT06575114 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self-determination theory-based health education measures
Description: In the control group, a conventional intervention will be used, and health education brochures on the COVID-19 vaccine will be distributed for the study participants to read on their own time. The intervention group will receive self-determination theory-based interventions, with targete interventions proposed based on the self-determination theory-including health-related talks and sharing sessions. To ensure that older individuals with varying levels of literacy understood the intervention, the process will be conducted in the local native dialect.
Study NCT06576414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: the first hour of ACT intervention followed by 1 hour of back exercise class, which led by a trained ACT counsellor and a trained exercise trainer
Study NCT06576414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: back exercise
Description: 1 hour of back exercise class led by a trained exercise trainer
Study NCT06576414 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: back exercise
Description: 1 hour of back exercise class led by a trained exercise trainer
Study NCT06576414 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: back care education
Description: 1 hour long interactive lesson to participants about LBP-related pathology, disability, psychology, and pain management skills.
Study NCT05707026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cross fiber fascial manipulation
Description: The group A received three sessions of fascial manipulation in two weeks. FM applied for 5 to 8 minutes at each point.
Study NCT05707026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching techniques(sleeper stretch and cross body adduction stretch)
Description: Group B received three sessions of sleeper and cross body adduction stretches. Group B received three sessions of sleeper stretch in a side lying position in 90o abduction, elbow at 90o flexion and then performing shoulder IR and cross-body adduction stretch was done in sitting position. Three sets of the each stretch position were held for 30 seconds with a 1 minute break between sets.
Study NCT05243433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery using the Maestro Platform
Description: Laparoscopic cholecystectomy, laparoscopic hernia repair, laparoscopic appendectomy, laparoscopic bariatric surgery (gastric sleeve or gastric bypass), or laparoscopic colectomy performed using the Maestro Platform.
Study NCT05601115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot assisted therapy
Description: In addition to the conventional treatment for 60 minutes in the RYT group, it was planned to perform robotic rehabilitation with a hand-finger robot \[Amadeo (Tyromotion, Graz, Austria)\] for 30 minutes, accompanied by a physiotherapist who is trained in the field of robotic rehabilitation and has at least 5 years of experience
Study NCT05601115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy Group
Description: An exercise program consisting of 45 minutes of range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) and 15 minutes of NMES was planned, accompanied by a physiotherapist experienced for at least 5 years in stroke rehabilitation, in the conventional therapy group.
Study NCT06524934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of virtual reality during the hysteroscopic procedure
Description: In VR group patients underwent hysteroscopy with standard care but the addition of VRT provided by a VR headset and headphones with the use of a Hypno VR software.
Study NCT05824065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMA102
Description: 1 mg
Study NCT05824065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMA102
Description: 2 mg
Study NCT05824065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: OMA102 - Placebo
Study NCT04768400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm I (MEP)
Description: Arm I (MEP): Motor evoked potential will be measured in various degree of the neuromuscular blockade.
Study NCT05895032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12-week exercise intervention
Study NCT05895032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: usual care
Study NCT05653791 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intestinal ultrasound
Description: Ulcerative colitis patients treated with filgotinib will undergo intestinal transabdominal ultrasound at baseline, week 4 and at the time of the follow-up endoscopy (week 10-16)
Study NCT05868057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280 tablets
Description: SHR7280 tablets 1 time
Study NCT05868057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280 dry suspension
Description: SHR7280 dry suspension 1 time
Study NCT05697848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy combined with Pain Education
Description: Patients with chronic low back pain receive manual therapy treatment combined with Pain Education sessions.
Study NCT05697848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Patients with chronic low back pain receive manual therapy treatment
Study NCT05885152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body electrical stimulation
Description: Performed using Miha Bodytec equipment, properly calibrated, with electrodes on the quadriceps, hamstrings, glutes, biceps, triceps, pectorals, abdomen, trapezius, latissimus dorsi and quadratus lumborum muscles.
Study NCT04250727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZYN
Description: 30 current non-treatment seeking adult smokers will be switched from smoking cigarettes to ZYN oral nicotine pouches containing either 3mg or 6mg concentration nicotine salts.
Study NCT05656599 — intervention group
Intervention type: DRUG
Intervention: Letermovir
Description: Patients received letermovir as prophylaxis or received preemptive therapy for CMV depends on clinical needs and patients' wishes
Study NCT04925206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET-01
Description: Recruited participants will receive ET-01 IV infusion following myeloablative conditioning with busulfan.
Study NCT05530083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group education
Description: Group education is one of strategies and behavioural interventions of smoking cessation. Lectures, group meeting for mutual support, discussion of coping skills and suggestions for prevention relapse can help smokers quit smoking by providing support and encouragement from people in same condition.
Study NCT05530083 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: conventional smoking cessation management
Description: Including regular follow-up of smoking status and giving advice of smoking cessation
Study NCT06528444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Grup 1 placebo
Description: placebo 1 capsule (6 mg) /day for 7 days.
Study NCT06528444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grup 2 dexametasona
Description: dexamethasone 1 capsule (6 mg)/day for 7 days
Study NCT06234852 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Glucocorticoid withdrawal group
Description: Gradual withdrawal of daily 5-mg prednisolone to daily 0-mg prednisolone over 20-24 weeks
Study NCT06234852 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoid maintenance group
Description: Daily 5-mg prednisolone over 24 weeks
Study NCT04958083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: multiphase ECG-gated contrast-enhanced CT
Description: Compared with current standard CT imaging, the dynamic CT protocol provides incremental functional information, which is potentially helpful to the individuals under study (such as early awareness for future complications and potential prediction of outcomes). Due to the nature of the acquisition, a wider R-R acquisition window will result in a higher radiation burden than a standard protocol. However, the study protocol will replace the standard routine CT image protocol as it contains both the routine anatomic information and incremental functional information. The time required for the image acquisition and associated radiation will be slightly higher; the additional information from multiple reconstructed phases will justify a slightly higher radiation burden in a usually elderly population. The estimated radiation dose for the standard imaging protocol is approximately 8 mSv. The estimated radiation dose for the modified dynamic CT image acquisition is approximately 18 mSv.
Study NCT06010472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR NK cells (KN5501)
Description: Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy.
Study NCT05969574 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transvaginal ultrasound
Description: Transvaginal ultrasound for antral follicle count (AFC) performed on the day of first consultation
Study NCT05969574 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test AMH
Description: Measurement of AMH performed on the day of first consultation
Study NCT06199258 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: pulmonary function test
Description: pulmonary function testing
Study NCT04740827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atogepant 60 mg
Description: Atogepant tablets.
Study NCT04740827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Atogepant matching placebo tablets.
Study NCT05038774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face to face Educational Training
Description: 1. Key points of current hypertension guidelines.~2. 10-step checklist how to obtain standardized upper arm blood pressure readings according to guidelines.~3. template of a blood pressure documentation sheet for serial documentation of blood pressure values by patients.~4. checklists to assist in the diagnosis of secondary hypertension.~5. Patient information leaflet about hypertension.
Study NCT05038774 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Printed Education Material
Description: 1. Key points of current hypertension guidelines.~2. 10-step checklist how to obtain standardized upper arm blood pressure readings according to guidelines.~3. template of a blood pressure documentation sheet for serial documentation of blood pressure values by patients.~4. checklists to assist in the diagnosis of secondary hypertension.~5. Patient information leaflet about hypertension.
Study NCT06184646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prune
Description: 30 g of prune/day
Study NCT03974620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support
Description: Individual Placement and Support is a vocational support program that was developed in the USA, to facilitate return to employment in individuals with severe and enduring mental illnesses.
Study NCT03974620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: This is an evidence based intervention that aims to improve cognitive functioning.
Study NCT05678764 — intervention group
Intervention type: DEVICE
Intervention: Conversational Information Collection Tool
Description: Conversational Information Collection Tool that facilitates the self-referral to talk therapy.
Study NCT04941599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-Hydroxybenzylamine
Description: 2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.
Study NCT04941599 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 250 mg three tabs TID (po) for 6 weeks.
Study NCT04993638 — intervention group
Intervention type: DEVICE
Intervention: hip arthroplasty
Description: Hip prosthesis surgery
Study NCT05749978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asana adjustment
Description: Adjust the operating table to 15° head height and foot low in advance. The patient is then slowly turned over from the transport table to the operating table and completed in the prone position. After the patient's hemodynamic stability is smooth, adjust the operating table to the level.
Study NCT06575764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Heart Priority Programme
Description: The programme is delivered by the Cardiac Rehabilitation (CR) team. It consist of two main parts: 1) an evidence-based identification form to identify patients at risk of dropout due to being in a vulnerable situation and 2) an add-on intervention to standard CR targeted these patients. The add-on intervention encompasses three core elements: 1) Assigning a contact person with specific responsibilities, 2) Systematically communicating patient information to colleagues in the CR team and 3) Systematic follow-up
Study NCT06487195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-facilitated, Recovery-based Self-illness-management programme
Description: The Peer-RESIM program will consist of 10 1.5-hour sessions (7-12 day intervals; 4 months), based on the modified CORE program workbook/manual and psychoeducation programmes developed by the research team.